Evidence map›Paper›PMID 30744630›Full record

ArticleRespiratory research2019

Effect of COPD severity and comorbidities on the result of the PHQ-9 tool for the diagnosis of depression: results from the COSYCONET cohort study.

Sarah Marietta von Siemens, Rudolf A Jörres, Jürgen Behr, Peter Alter, Johanna Lutter, Tanja Lucke, Sandra Söhler, Tobias Welte, Henrik Watz, Claus F Vogelmeier and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01245933 (Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01245933 completednot on this map

Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD

TypeobservationalSponsorPhilipps University MarburgRan2010 to 2023Enrolled2,741ConditionsChronic Obstructive Pulmonary Disease (COPD)
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. The Diagnosis and Treatment of COPD and Its Comorbidities.Deutsches Arzteblatt international · 2023
    Review
  10. Article
  11. Relationship between serum Th1/Th2 imbalance and depression in elderly patients with COPD and its clinical implications.Technology and health care : official journal of the European Society for Engineering and Medicine · 2023
    Article
  12. Physical Activity, Depression and Quality of Life in COPD - Results from the CLARA II Study.International journal of chronic obstructive pulmonary disease · 2023
    Article
  13. Review
  14. Article
  15. Observational
  16. Comparative Impact of Depressive Symptoms and FEVAnnals of the American Thoracic Society · 2022
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Sarah Marietta von SiemensInstitute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich (CPC-M), Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336, Munich, Germany.
Rudolf A JörresInstitute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich (CPC-M), Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336, Munich, Germany.
Jürgen BehrDepartment of Internal Medicine V, University of Munich (LMU), Ziemssenstr. 1, 80336, Munich, Germany.
Peter AlterDepartment of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany, Member of the German Center for Lung Research (DZL), Baldingerstrasse, 35043, Marburg, Germany.
Johanna LutterInstitute of Health Economics and Health Care Management, Helmholtz Zentrum München GmbH - German Research Center for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research, Ingolstädter Landstr. 1, 85764, Munich, Germany.
Tanja LuckeInstitute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich (CPC-M), Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336, Munich, Germany.
Sandra SöhlerASCONET Study Coordination Office, University of Marburg, Baldingerstraße, 35043, Marburg, Germany.
Tobias WelteDepartment of Pneumology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625, Hannover, Germany.
Henrik WatzPulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Center North, Member of the German Center for Lung Research, Woehrendamm 80, 22927, Grosshansdorf, Germany.
Claus F VogelmeierDepartment of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany, Member of the German Center for Lung Research (DZL), Baldingerstrasse, 35043, Marburg, Germany.
Franziska TrudzinskiDepartment of Internal Medicine V - Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital, Kirrberger Straße 1, 66424, Homburg, Germany.
Winfried RiefDepartment of Clinical Psychology and Psychotherapy, Philipps-University Marburg, Germany, Gutenbergstraße 18, 35032, Marburg, Germany.
Britta HerbigInstitute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Comprehensive Pneumology Center Munich (CPC-M), Ludwig-Maximilians-Universität München, Ziemssenstr. 1, 80336, Munich, Germany.
Kathrin KahnertDepartment of Internal Medicine V, University of Munich (LMU), Ziemssenstr. 1, 80336, Munich, Germany. Kathrin.Kahnert@med.uni-muenchen.de.
COSYCONET study group
Ludwig-Maximilians-Universität München · DEPhilipps University of Marburg · DEGerman Center for Lung Research · DEHelmholtz Zentrum München · DEMedizinische Hochschule Hannover · DETechnical University of Munich · DE

Funding

AstraZeneca GmbH not applicableBayer Schering Pharma AG not applicableBoehringer Ingelheim Pharma GmbH & Co. KG not applicableChiesi GmbH not applicableGerman Federal Ministry of Education and Research 01 GI 0881GlaxoSmithKline not applicableGrifols Deutschland GmbH not applicableMSD Sharp & Dohme GmbH not applicableMundipharma GmbH not applicableNovartis Deutschland GmbH not applicablePfizer Pharma GmbH not applicableTakeda Pharma Vertrieb GmbH & Co not applicable
6 · The paper itself

Abstract

The diagnosis of depression, a frequent comorbidity of chronic obstructive pulmonary disease (COPD), is often supported by questionnaires, such as the Patient Health Questionnaire 9 (PHQ-9). It is unknown to which extent its single questions are affected by the clinical characteristics of COPD patients.We addressed this question in 2255 GOLD grade 1-4 patients from the COSYCONET (COPD and Systemic Consequences - Comorbidities Network) COPD cohort. The dependence on COPD severity was assessed using symptoms, exacerbation risk (GOLD A-D; modified Medical Research Council dyspnoea scale (mMRC)), and frequent comorbidities as predictors of PHQ-9 results, while including age, gender, body mass index (BMI) and smoking habits as covariates.Symptoms and exacerbation risk were associated with depression in an additive manner, with mean elevations in the PHQ-9 sum score by 2.75 and 1.44 points, respectively. Asthma, sleep apnoea, gastrointestinal disorders, osteoporosis and arthritis were linked to increases by 0.8 to 1.3 points. Overall, the COPD characteristics contributed to the mean PHQ-9 score by increases from 4.5 or 5.2 to 6.3 points, respectively, when either taking GOLD A as reference or the absence of comorbidities. This finding was independent of the diagnosis of mental disorder or the intake of antidepressants. The presence of COPD led to an increase in the proportion of scores indicating depression from 12 to 22%. Single item analysis revealed homogenous effects regarding GOLD groups, but heterogeneous effects regarding GOLD grades.These findings indicate specific effects of COPD severity on the PHQ-9 depression score, especially symptoms and exacerbation risk, explaining the high prevalence of depression in COPD. Alternative explanations like an overlap of COPD severity and PHQ-9 items are discussed. Of note, we also found COPD treatment effects on depression scores.

Indexed as

AgedAge FactorsBody Mass IndexCohort StudiesComorbidityDepressionFemaleHumansMaleMiddle AgedPatient Health QuestionnairePrevalencePulmonary Disease, Chronic ObstructiveSex FactorsSmokingSurveys and QuestionnairesCOPDDepressionPHQ-9

Identifiers

PMID30744630
PMCPMC6371561
OpenAlexW2915026708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.